Page last updated: 2024-11-13
aspulvinone E
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
4-hydroxy-5-(4-hydroxybenzylidene)-3-(4-hydroxyphenyl)furan-2(5H)-one : A member of the class of butenolides that is furan-2(5H)-one substituted by 4-hydroxyphenyl, hydroxy and 4-hydroxybenzylidene groups at positions 3, 4 and 5, respectively. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
aspulvinone E : A 4-hydroxy-5-(4-hydroxybenzylidene)-3-(4-hydroxyphenyl)furan-2(5H)-one in which the double bond adopts a Z-configuration. It is a marine metabolite isolated from the fungus Aspergillus terreus and exhibits antiviral activity. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 54675753 |
| CHEMBL ID | 2337339 |
| CHEBI ID | 17704 |
Synonyms (21)
| Synonym |
|---|
| (5z)-4-hydroxy-3-(4-hydroxyphenyl)-5-[(4-hydroxyphenyl)methylidene]furan-2(5h)-one |
| CHEBI:17704 , |
| (5z)-4-hydroxy-5-(4-hydroxybenzylidene)-3-(4-hydroxyphenyl)furan-2(5h)-one |
| (5z)-4-hydroxy-3-(4-hydroxyphenyl)-5-[(4-hydroxyphenyl)methylene]-2(5h)-furanone |
| 49637-60-7 |
| C02006 , |
| aspulvinone e |
| 4-hydroxy-5-(4-hydroxybenzylidene)-3-(4-hydroxyphenyl)furan-2(5h)-one |
| NCGC00183583-01 |
| NCGC00183583-02 |
| CHEMBL2337339 |
| CCG-208773 |
| Q27102544 |
| bdbm50453556 |
| g24nr54fg4 , |
| aspergillide b1 |
| (5z)-4-hydroxy-3-(4-hydroxyphenyl)-5-((4-hydroxyphenyl)methylene)-2(5h)-furanone |
| 2(5h)-furanone, 4-hydroxy-3-(4-hydroxyphenyl)-5-((4-hydroxyphenyl)methylene)-, (5z)- |
| unii-g24nr54fg4 |
| DTXSID201317721 |
| AKOS040734842 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Roles (4)
| Role | Description |
|---|---|
| Aspergillus metabolite | Any fungal metabolite produced during a metabolic reaction in the mould, Aspergillus. |
| marine metabolite | Any metabolite produced during a metabolic reaction in marine macro- and microorganisms. |
| antiviral agent | A substance that destroys or inhibits replication of viruses. |
| EC 3.2.1.20 (alpha-glucosidase) inhibitor | An EC 3.2.1.* (glycosidase) inhibitor that interferes with the action of alpha-glucosidase (EC 3.2.1.20). |
| [role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
Drug Classes (2)
| Class | Description |
|---|---|
| aspulvinone | |
| 4-hydroxy-5-(4-hydroxybenzylidene)-3-(4-hydroxyphenyl)furan-2(5H)-one | A member of the class of butenolides that is furan-2(5H)-one substituted by 4-hydroxyphenyl, hydroxy and 4-hydroxybenzylidene groups at positions 3, 4 and 5, respectively. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
Protein Targets (4)
Inhibition Measurements
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Maltase-glucoamylase, intestinal | Homo sapiens (human) | IC50 (µMol) | 400.0000 | 0.0400 | 3.4652 | 9.0000 | AID1370806 |
| Lysosomal alpha-glucosidase | Homo sapiens (human) | IC50 (µMol) | 400.0000 | 0.0600 | 2.2889 | 7.8000 | AID1370806 |
| Sucrase-isomaltase, intestinal | Homo sapiens (human) | IC50 (µMol) | 400.0000 | 0.0490 | 2.7294 | 7.8000 | AID1370806 |
| Probable maltase-glucoamylase 2 | Homo sapiens (human) | IC50 (µMol) | 400.0000 | 0.5400 | 4.0244 | 7.8000 | AID1370806 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
Biological Processes (23)
Molecular Functions (10)
Ceullar Components (14)
Bioassays (13)
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1370807 | Antioxidant activity assessed as DPPH radical scavenging activity incubated for 30 mins under dark condition by spectrophotometric analysis | 2018 | Bioorganic & medicinal chemistry letters, 02-01, Volume: 28, Issue:3 | New butenolide derivatives from the marine sponge-derived fungus Aspergillus terreus. |
| AID1503177 | Cytotoxicity against human SupT1 cells assessed as decrease in cell viability after 48 hrs by CCK-8 assay | 2017 | Journal of natural products, 10-27, Volume: 80, Issue:10 | Metabolites from the Plant Endophytic Fungus Aspergillus sp. CPCC 400735 and Their Anti-HIV Activities. |
| AID1370806 | Inhibition of alpha-glucosidase (unknown origin) using p-nitro-phenyl-alpha-D-glucopyranoside as substrate preincubated for 5 mins with substrate followed by enzyme addition measure after 15 mins by spectrophotometric method | 2018 | Bioorganic & medicinal chemistry letters, 02-01, Volume: 28, Issue:3 | New butenolide derivatives from the marine sponge-derived fungus Aspergillus terreus. |
| AID730331 | Antiviral activity against Influenza A virus (A/Puerto Rico/8/1934(H1N1)) infected in MDCK cells assessed as protection against virus-induced cytopathic effect after 48 hrs by crystal violet staining method | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6 | Aspulvinones from a mangrove rhizosphere soil-derived fungus Aspergillus terreus Gwq-48 with anti-influenza A viral (H1N1) activity. |
| AID730332 | Cytotoxicity against human A549 cells assessed as cell viability after 72 hrs by MTT assay | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6 | Aspulvinones from a mangrove rhizosphere soil-derived fungus Aspergillus terreus Gwq-48 with anti-influenza A viral (H1N1) activity. |
| AID1272001 | Inhibition of Saccharomyces cerevisiae alpha-Glucosidase using p-nitrophenyl-alpha-D-glucopyranoside as substrate assessed as formation of para-nitrophenol preincubated for 5 mins followed by addition of substrate measured after 15 mins by microplate read | 2016 | Bioorganic & medicinal chemistry letters, Jan-15, Volume: 26, Issue:2 | Polyketide butenolide, diphenyl ether, and benzophenone derivatives from the fungus Aspergillus flavipes PJ03-11. |
| AID730330 | Cytotoxicity against MDCK cells assessed as cell viability after 72 hrs by MTT assay | 2013 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6 | Aspulvinones from a mangrove rhizosphere soil-derived fungus Aspergillus terreus Gwq-48 with anti-influenza A viral (H1N1) activity. |
| AID1853815 | Antibacterial activity against Staphylococcus aureus ATCC 25923 assessed as bacterial growth inhibition | 2022 | European journal of medicinal chemistry, Feb-15, Volume: 230 | Natural products from mangrove sediments-derived microbes: Structural diversity, bioactivities, biosynthesis, and total synthesis. |
| AID1503176 | Antiviral activity against VSV-G pseudotyped HIV1 infected in human SupT1 cells after 48 hrs by luciferase reporter gene assay | 2017 | Journal of natural products, 10-27, Volume: 80, Issue:10 | Metabolites from the Plant Endophytic Fungus Aspergillus sp. CPCC 400735 and Their Anti-HIV Activities. |
| AID1503175 | Antiviral activity against VSV-G pseudotyped HIV1 infected in human SupT1 cells at 100 uM after 48 hrs by luciferase reporter gene assay relative to control | 2017 | Journal of natural products, 10-27, Volume: 80, Issue:10 | Metabolites from the Plant Endophytic Fungus Aspergillus sp. CPCC 400735 and Their Anti-HIV Activities. |
| AID1347082 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID1347086 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID1347083 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
Research
Studies (6)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (66.67) | 24.3611 |
| 2020's | 2 (33.33) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 12.63
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.63) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 1 (16.67%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (83.33%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||